Wall Street analysts are presenting a mixed outlook for the upcoming Q4 2025 earnings reports of Insulet (PODD) and Moody's (MCO). For Insulet, projections indicate earnings per share of $1.48 and revenues of $767.33 million. However, a negative Earnings ESP of -6.63% combined with a Zacks Rank of #4 suggests a potential earnings miss for the medical device company. Conversely, Moody's is anticipated to report robust results, with an estimated EPS of $3.46 and revenues reaching $1.88 billion. The credit rating giant benefits from a positive Earnings ESP of +0.78% and a favorable Zacks Rank of #2, signaling a strong likelihood of exceeding analyst estimates. This divergence in pre-earnings indicators highlights varying probabilities for individual stock performance ahead of their financial disclosures.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis